Drug-induced (steroid) glaucoma and ophthalmic hypertension
https://doi.org/10.52485/19986173_2022_4_122
Abstract
Drug-induced (steroid) ophthalmohypertension and glaucoma is an actual problem due to the widespread use of glucocorticoids in treatment of various ocular and systemic diseases. Intraocular pressure may increase with different routes of glucocorticoid administration, at different times of treatment and can also stop on its own after discontinuation of these drugs. Prolonged uncontrolled glucocorticoid administration may cause persistent morphological optic nerve damage with perimetric loss. The literature review presents risk factors, mechanisms of eye hydrodynamic disturbances, clinical course features and principles of secondary steroid ophthalmohypertension and glaucoma treatment.
About the Authors
E. S. Taskina
Chita State Medical Academy
Russian Federation
Russian Federation
39a Gorky Street, Chita, 6720000
S. V. Kharintseva
Chita State Medical Academy
Russian Federation
Russian Federation
39a Gorky Street, Chita, 6720000
E. V. Prosekina
Chita State Medical Academy
Russian Federation
Russian Federation
39a Gorky Street, Chita, 6720000
References
1. Gloria R., Oddone F., Agnifili L., Katsanos A., Michelessi M., Mastropasqua L., Quaranta L., Riva I., Tanga L., Manni G. Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management. Surv Ophthalmol. 2020. 65(4). 458-472. DOI: 10.1016/j.survophthal.2020.01.002.
2. Steven T., Souffriau J., Libert C. A General Introduction to Glucocorticoid Biology. Front Immunol. 2019. 10. 15-45. DOI:10.3389/fimmu.2019.01545.
3. Borisova E.O. Undesirable effects of systemic glucocorticosteroid therapy. Clinical gerontology. 2009. 8-9. 19-26. in Russian.
4. Vitovskaya O.P. Medically induced glaucoma. Ophthalmological records. 2014. 3. 58-62. in Russian.
5. Musleh M.G., Bokre D., Dahlmann-Noor A.H. Risk of intraocular pressure elevation after topical steroids in children and adults: A systematic review. Eur J Ophthalmol. 2020. 30(5). 856-866. DOI: 10.1177/1120672119885050.
6. McLean J.M. Use of ACTH and cortisone Trans. Am. Ophthalmol Soc. 1950. 48. 293-296.
7. Francois J. Cortisone et tension oculaire. Ann D’Oculist. 1954. 187. 805.
8. Armaly M.F. Statistical attributes of the steroid hypertensive response in the clinically normal eye. 1. The demonstration of three level of response. Invest Opbtbalmol. 1963. 4. 187-197.
9. Nuyen B., Weinreb R.N., Robbins S.L. Steroid-induced glaucoma in the pediatric population. J AAPOS. 2017. 21(1). 1-6. DOI: 10.1016/j.jaapos.2016.09.026.
10. Choi W., Bae H.W., Choi E.Y., Kim M., Kim E.W., Kim C.Y., Kim M., Seong G.J. Age as a risk factor for steroid-induced ocular hypertension in the non-paediatric population. Br J Ophthalmol. 2020. 104(10). 1423-1429. DOI: 10.1136/bjophthalmol-2019-314559.
11. Gupta S., Shah P., Grewal S., Chaurasia A.K., Gupta V. Steroid-induced glaucoma and childhood blindness. Br J Ophthalmol. 2015. 99(11). 1454-1456. DOI: 10.1136/bjophthalmol-2014-306557.
12. Lam D.S.C., Fan D.S.P., Ng J.S.K., Yu C.B.O., Wong C.Y., Cheung A.Y.K. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin. Exp. Ophthalmol. 2005. 33. 252-258. DOI: 10.1111/j.1442-9071.2005.01022.x.
13. Armaly M.F. Effect of corticosteroids on intraocular pressure and fluid dynamics: II. The effect of dexamethasone on the glaucomatous eye. Arch. Ophthalmol. 1963. 70. 492-499.
14. Zhang X., Ognibene C.M., Clark A.F., Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res. 2007. 84(2). 275-284. DOI: 10.1016/j.exer.2006.09.022.
15. Buttgereit F., Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids. 2002. 67. 529- 534. DOI: 10.1016/S0039-128X(01)00171-4.
16. Stahn C., Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008. 4. 525-533. DOI: 10.1038/ncprheum0898.
17. Umberto M.G., Chrousos G.P. General Adaptation in Critical Illness: Glucocorticoid Receptor- alpha Master Regulator of Homeostatic Corrections. Front Endocrinol (Lausanne). 2020. 11. 161. DOI:10.3389/fendo.2020.0016.
18. Ioanna P., Dejager L., Ballegeer M., Lievens S., Tavernier J., Bosscher K.De, Libert C. The Interactome of the Glucocorticoid Receptor and Its Influence on the Actions of Glucocorticoids in Combatting Inflammatory and Infectious Diseases. Microbiol Mol Biol Rev. 2016. 80(2). 495- 522. DOI:10.1128/MMBR.
19. Escoter-Torres L., Caratti G., Mechtidou A., Tuckermann J., Uhlenhaut N.H., Vettorazzi S. Fighting the Fire: Mechanisms of Inflammatory Gene Regulation by the Glucocorticoid Receptor. Front Immunol. 2019. 10. 1859. DOI:10.3389/fimmu.2019.01859.
20. Vranka J.A., Kelley M.J., Acott T.S., Keller K.E. Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma. Experimental eye research. 2015. 133. 112-125. DOI: 10.1016/j.exer.2014.07.014.
21. Clark A.F., Wordinger R.J. The role of steroids in outflow resistance. Exp Eye Res. 2009. 88. 752-759. DOI: 10.1016/j.exer.2008.10.004.
22. Overby D.R., Clark A.F. Animal models of glucocorticoid-induced glaucoma. Exp Eye Res. 2015. 141. 15-22. DOI: 10.1016/j.exer.2015.06.002.
23. Yun A.J., Murphy C.G., Polansky J.R., Newsome D.A., Alvarado J.A. Proteins secreted by human trabecular cells: glucocorticoid and other effects. Invest Ophthalmol Vis Sci. 1989. 30. 2012-2022.
24. Zode G.S., Kuehn M.H., Nishimura D.Y., Searby C.C., Mohan K., Grozdanic S.D., Bugge K., Anderson M.G., Clark A.F., Stone E.M., Sheffield V.C. Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma. J Clin Invest. 2015. 125. 3303. DOI: 10.1172/JCI58183.
25. Patel G.C., Phan T.N., Maddineni P., Kasetti R.B., Millar J.C., Clark A.F., Zode G.S. Dexamethasone induced ocular hypertension in mice: effects of myocilin and route of administration. Am J Pathol. 2017. 187(4). 713-723. DOI: 10.1016/j.ajpath.2016.12.003.
26. Sheppard J.D., Comstock T.L., Cavet M.E. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther. 2016. 33. 532-552. DOI: 10.1007/s12325-016-0315-8.
27. Kiddee W., Trope G., Sheng L., Beltran-Agullo L., Smith M., Strungaru M., Baath J., Buys Y. Intraocular Pressure Monitoring Post Intravitreal Steroids: A Systematic Review. Survey of Ophthalmology. 2013. 58(4). 291-310. DOI: 10.1016/j.survophthal.2012.08.003.
28. Yuksel-Elgin C., Elgin C. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection: a Meta-analysis. Int J Ophthalmol. 2016. 9(1). 139-144. DOI: 10.18240/ijo.2016.01.23.
29. Ghoneim E.M., Abd E.l., Ghany A.A. Behavior of intraocular pressure after intravitreal injection of triamcinolone acetonide among Egyptians. Ophthalmol Ter. 2013. 2(2). 121-130. DOI: 10.1007/s40123-013-0017-0.
30. Goni F. J., Stalmans I., Denis P., Nordmann J.-P., Taylor S., Diestelhorst M., Figueiredo A.R., Garway-Heath D.F. Elevated Intraocular Pressure after Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management. Ophthalmology and Therapy. 2016. 5(1). 47-61. DOI: 10.1007/s40123-016-0052-8.
31. Groth S.L., Albeiruti E., Nunez M., Fajardo R., Sharpsten L., Loewen N., Schuman J.S., Goldberg J.L. SALT Trial: Steroids after Laser Trabeculoplasty: Impact of Short-Term Anti-inflammatory Treatment on Selective Laser Trabeculoplasty Efficacy. Ophthalmology. 2019. 126(11). 1511- 1516. DOI: 10.1016/j.ophtha.2019.05.032.
32. Candia O.A., Gerometta R.M., Danias J. Tissue plasminogen activator reduces the elevated intraocular pressure induced by prednisolone in sheep. Exp Eye Res. 2014. 128. 114-116. DOI: 10.1016/j.exer.2014.10.004.
33. Gerometta R., Kumar S., Shah S., Alvarez L., Candia O., Danias J. Reduction of steroidinduced intraocular pressure elevation in sheep by tissue plasminogen activator. Invest Ophthalmol Vis Sci. 2013. 54(13). 7903-7909. DOI: 10.1167/iovs.13-12801.
Review
For citations:
Taskina E.S., Kharintseva S.V., Prosekina E.V. Drug-induced (steroid) glaucoma and ophthalmic hypertension. Transbaikalian Medical Bulletin. 2022;(4):122-131. (In Russ.) https://doi.org/10.52485/19986173_2022_4_122
Views:
136
Email this article 